Eupraxia Pharmaceuticals Inc.

Toronto Stock Exchange EPRX.TO

Eupraxia Pharmaceuticals Inc. Net Income Margin for the year ending December 31, 2023

Eupraxia Pharmaceuticals Inc. Net Income Margin is NA for the year ending December 31, 2023. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
SV Wall Street
Toronto Stock Exchange: EPRX.TO

Eupraxia Pharmaceuticals Inc.

CEO Dr. James A. Helliwell FRCPC, M.D.
IPO Date March 9, 2021
Location Canada
Headquarters 2067 Cadboro Bay Road
Employees 29
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

StockViz Staff

February 6, 2025

Any question? Send us an email